Clinical Trial Update: Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial [Phase 1, Phase 2]

View source ↗

Summary

The ImmunoPeCa trial, an immunotoxin therapy for colorectal cancer with peritoneal carcinomatosis, has completed Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Peritoneal Carcinomatosis

Snippet

Sponsor: Oslo University Hospital | Conditions: Colorectal Neoplasms | Phase 1, Phase 2 | Status: COMPLETED